We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+1.18%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.05B
AUM Growth
-$75.9M
Cap. Flow
-$65.9M
Cap. Flow %
-6.27%
Top 10 Hldgs %
87.03%
Holding
23
New
6
Increased
5
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
IRTC icon
iRhythm Holdings
IRTC
+$54.5M
2
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$27.6M
3
APEN
Apollo Endosurgery, Inc.
APEN
+$22.2M
4
KALV
KalVista Pharmaceuticals
KALV
+$21.4M
5
XLRN
Acceleron Pharma
XLRN
+$10.7M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$167M
2
VTI icon
Vanguard Total Stock Market ETF
VTI
+$59.8M

Sector Composition

Rank Sector Weight
1 Healthcare 71.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INGN icon
1
Inogen
INGN
$167M
$238M 22.7%
3,549,320
– –
VTI icon
2
Vanguard Total Stock Market ETF
VTI
$654B
$187M 17.83%
1,623,100
-532,000
-25% -$59.8M
CLCD
3
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$115M 10.94%
3,156,563
– –
VGK icon
4
Vanguard FTSE Europe ETF
VGK
$30B
$101M 9.59%
2,101,000
– –
RETA
5
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$73.5M 7%
3,367,763
– –
IRTC icon
6
iRhythm Holdings
IRTC
$3.59B
$60.7M 5.78%
+2,024,448
New +$54.5M
CRVS icon
7
Corvus Pharmaceuticals
CRVS
$1.1B
$46.1M 4.39%
3,224,046
– –
XLRN
8
DELISTED
Acceleron Pharma
XLRN
$31.6M 3.01%
1,240,173
+336,340
+37% +$10.7M
RARX
9
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$30.9M 2.94%
+2,031,562
New +$27.6M
MRUS
10
DELISTED
Merus
MRUS
$29.8M 2.84%
1,410,417
– –
SPNC
11
DELISTED
Spectranetics Corp
SPNC
$28.9M 2.75%
1,179,122
+23,400
+2% +$550K
FLXN
12
DELISTED
Flexion Therapeutics, Inc.
FLXN
$26.6M 2.53%
1,397,718
+300,000
+27% +$5.73M
KALV
13
DELISTED
KalVista Pharmaceuticals
KALV
$20.5M 1.95%
+2,901,927
New +$21.4M
APEN
14
DELISTED
Apollo Endosurgery, Inc.
APEN
$17.7M 1.69%
+1,456,972
New +$22.2M
NBRV
15
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$13.9M 1.32%
9,306
+4,839
+108% +$6.42M
IVTY
16
DELISTED
Invuity, Inc
IVTY
$7.58M 0.72%
1,318,448
+33,000
+3% +$276K
DERM
17
DELISTED
Dermira, Inc.
DERM
$6.57M 0.63%
+216,562
New +$6.98M
WMGIZ
18
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
– –
0
– –
CRSP icon
19
CRISPR Therapeutics
CRSP
$4.58B
$4.52M 0.43%
+223,317
New +$4.17M
HTGM
20
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$2.87M 0.27%
7,112
– –
XENE icon
21
Xenon Pharmaceuticals
XENE
$6.32B
$982K 0.09%
127,563
– –
OPK icon
22
Opko Health
OPK
$921M
$2K ﹤0.01%
259
– –
ISEE
23
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-3,610,487
Closed -$167M

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q4 2016 Portfolio in Review

As of Q4 2016, Novo Holdings A/S held 23 positions worth $1.05B, down 6.7% from $1.13B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Novo Holdings A/S withdrew a net $65.9M in Q4 2016, closing 1 position and reducing 1 holding. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $167M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 69% a quarter earlier.

Against the trend, Novo Holdings A/S opened a new position in iRhythm Holdings worth $60.7M.

  • Novo Holdings A/S's largest Q4 2016 buy was iRhythm Holdings: 2,024,448 shares worth $60.7M.
  • Novo Holdings A/S added most to Acceleron Pharma in Q4 2016, an estimated $10.7M increase.
  • Novo Holdings A/S's biggest Q4 2016 reduction was Vanguard Total Stock Market ETF, cutting an estimated $59.8M.
  • Novo Holdings A/S fully exited IVERIC bio, Inc. Common Stock in Q4 2016, selling an estimated $167M.
  • Novo Holdings A/S's ten largest holdings make up 87% of its $1.05B portfolio in Q4 2016.
  • Novo Holdings A/S opened 6 new positions and closed 1 in Q4 2016.
  • Novo Holdings A/S's portfolio value fell 6.7% quarter-over-quarter to $1.05B.

Based on Novo Holdings A/S's 13F filing for Q4 2016, filed 14 Feb 2017.